Fintel reports that Jpmorgan Chase & Co has filed a 13G/A form with the SEC disclosing ownership of 4.98MM shares of Revance Therapeutics Inc (RVNC). This represents 6.0% of the company. In their previous filing dated January 18, 2022 they reported 6.79MM shares and 9.40% of the company, a…
#jpmorganchaseco #revancetherapeutics #eps #paloaltoinvestorslp #vtsmx #revance #injection #fda #mylannv #I am a spammer ban me
Continue reading...